帕金森病患者冷漠与临床及神经认知因素的横断面和纵向关联
在新西兰帕金森病进展项目346例患者、最长14年随访共1392次评估中,冷漠出现率约11%或22%(取决于NPI cutoff),不随病程显著变化;冷漠与死亡风险升高相关(HR=2.92),认知下降、抑郁和运动严重度可预测冷漠发生。
要点
- 冷漠在帕金森病全程出现率约11%或22%,与病程无显著关联。
- 冷漠者死亡风险显著升高(HR=2.92,95%CI 1.50-5.66)。
- 认知下降、抑郁和运动严重度预测无动机缺陷者发生冷漠。
核心结论
- 冷漠在帕金森病全程均可出现,与较高死亡风险相关。
- 抑郁症状和认知障碍尤其能预测动机正常者未来发生冷漠。
研究设计与样本
- 纵向新西兰帕金森病进展项目队列,纳入346例帕金森病患者,最长随访14年,共1392次评估。
- 采用横断面贝叶斯回归和多状态预测模型,并考虑死亡竞争风险。
主要发现
- 冷漠出现率不随病程显著变化(病程OR=0.55,95%CI 0.28-1.12),任意时间约11%或22%取决于NPI cutoff。
- 控制其他因素后,冷漠与死亡风险显著升高相关(HR=2.92,95%CI 1.50-5.66)。
- 在无动机缺陷者中,较低认知(HR=0.66,95%CI 0.48-0.90)、较高抑郁(HR=1.45,95%CI 1.04-2.02)和较大运动严重度(HR=1.37,95%CI 1.01-1.86)预测冷漠发生。
- 横断面分析中,认知(OR=0.58,95%CI 0.44-0.76)、抑郁(OR=1.43,95%CI 1.04-1.97)、女性(OR=0.45,95%CI 0.22-0.92)与冷漠相关,左旋多巴等效剂量(OR=0.78,95%CI 0.59-1.04)可能相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: A robust understanding of the natural history of apathy in Parkinson disease (PD) is foundational for developing effective clinical management tools. However, large longitudinal studies are lacking while the literature is inconsistent about even cross-sectional associations. We aimed to determine the longitudinal predictors of apathy development in a large cohort of people with PD and its cross-sectional associations and trajectories over time, using sophisticated Bayesian modeling techniques. METHODS: People with PD followed up in the longitudinal New Zealand Parkinson's progression project were included. Apathy was defined using the neuropsychiatric inventory subscale ≥4, and analyses were also repeated using a less stringent cutoff of ≥1. Both MoCA and comprehensive neuropsychological testing were used as appropriate to the model. Depression was assessed using the hospital anxiety and depression scale. Cross-sectional Bayesian regressions were conducted, and a multistate predictive model was used to identify factors that predict the initial onset of apathy in nonapathetic PD, while also accounting for the competing risk of death. The relationship between apathy presence and mortality was also investigated. RESULTS: Three hundred forty-six people with PD followed up for up to 14 years across a total of 1,392 sessions were included. Apathy occurrence did not vary significantly across the disease course (disease duration odds ratio [OR] = 0.55, [95% CI 0.28-1.12], affecting approximately 11% or 22% of people at any time depending on the NPI cutoff used. Its presence was associated with a significantly higher risk of death after controlling for all other factors (hazard ratio [HR] = 2.92 [1.50-5.66]). Lower cognition, higher depression levels, and greater motor severity predicted apathy development in those without motivational deficits (HR [cognition] = 0.66 [0.48-0.90], HR [depression] = 1.45 [1.04-2.02], HR [motor severity] = 1.37 [1.01-1.86]). Cognition and depression were also associated with apathy cross-sectionally, along with male sex and possibly lower dopaminergic therapy level, but apathy still occurred across the full spectrum of each variable (OR [cognition] = 0.58 [0.44-0.76], OR [depression] = 1.43 [1.04-1.97], OR [female sex] = 0.45 [0.22-0.92], and OR [levodopa equivalent dose] = 0.78 [0.59-1.04]. DISCUSSION: Apathy occurs across the PD time course and is associated with higher mortality. Depressive symptoms and cognitive impairment in particular predict its future development in those with normal motivation.
引用
- Le Heron C, Horne KL, MacAskill MR, et al. Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease. Neurology. 2024. PMID: 38830182. doi:10.1212/WNL.0000000000209301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。